Does Cosentyx Dosage Change with Weight?
Cosentyx (secukinumab) dosage does not adjust based on patient weight or body size. It uses fixed dosing across approved indications for adults and children.[1][2]
Standard Adult Dosing by Condition
- Psoriasis: 300 mg subcutaneous injection at weeks 0, 1, 2, 3, then every 4 weeks. Split into two 150 mg injections if using prefilled syringes or autoinjectors.[1]
- Psoriatic arthritis or ankylosing spondylitis: 150 mg subcutaneous at weeks 0, 1, 2, 3, then every 4 weeks. Increase to 300 mg in some cases if response is inadequate.[1]
- Non-radiographic axial spondyloarthritis: 150 mg subcutaneous at weeks 0, 1, 2, 3, then every 4 weeks.[1]
- Hidradenitis suppurativa: 300 mg subcutaneous at weeks 0, 1, 2, 3, then every 4 weeks.[1]
Intravenous loading doses (300 mg at week 0, 150 mg at week 2, 300 mg at week 4) apply for some indications before switching to subcutaneous.[1]
Pediatric Dosing for Psoriasis (Ages 6+)
Fixed doses based on weight bands, not proportional to body weight:
- 50 kg or more: 300 mg (two 150 mg injections).
- 15 to <50 kg: 150 mg (one 150 mg injection).
- <15 kg or more: Not recommended.[1][2]
This stepped approach accounts for smaller body sizes without linear scaling.
Why No Weight-Based Adjustment?
Cosentyx pharmacokinetics show exposure varies modestly with body weight (about 25-30% difference between low and high weights), but clinical trials confirmed fixed doses achieve similar efficacy and safety across BMI ranges. No adjustments needed for obesity or underweight patients.[3][4]
Considerations for Obese Patients
Higher body weight links to slightly lower drug exposure, but studies (including post-hoc analyses) show no loss of efficacy in psoriasis or arthritis patients with BMI over 30. Dose escalation to 300 mg occurs based on clinical response, not weight alone.[4][5] No specific warnings for extreme weights in labeling.
What If a Patient's Weight Changes?
Reassess pediatric weight bands if it crosses thresholds (e.g., from 150 mg to 300 mg at 50 kg). Adults stay on fixed regimen unless response falters.[1]
[1]: Cosentyx Prescribing Information (Novartis, 2024)
[2]: FDA Label for Cosentyx
[3]: Pharmacokinetics of Secukinumab in Obese Patients (J Clin Pharmacol, 2018)
[4]: Efficacy Across Weight Groups (J Am Acad Dermatol, 2020)
[5]: No DrugPatentWatch.com data; patents focus on formulation, not weight dosing (expires 2025-2031)